<DOC>
	<DOCNO>NCT00238953</DOCNO>
	<brief_summary>Clinical trial novo transplant recipient , aim assess tolerability safety clinical outcome EC-MPS combination cyclosporine microemulsion ( CsA-ME ) without steroid population kidney transplant recipient .</brief_summary>
	<brief_title>Efficacy Safety Enteric-coated Mycophenolate Sodium ( EC-MPS ) de Novo Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criterion : Male female age 18 75 Recipients cadaveric , live unrelated living relate kidney transplant , treat CsAME , without corticosteroid , primary immunosuppression Exclusion criterion : Multiorgan recipient ( e.g . kidney pancreas ) previous transplant organ , kidney . Patients know hypersensitivity MPA , ECMPS component formulation ( e.g . lactose ) . Patients thrombocytopenia ( &lt; 75,000/mm3 ) , absolute neutrophil count &lt; 1,500/mm3 , and/or leukocytopenia ( &lt; 2,500/mm3 ) , and/or hemoglobin &lt; 6 g/dL Screening Baseline . Other inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Kidney transplantation</keyword>
	<keyword>enteric-coated mycophenolate sodium</keyword>
</DOC>